Monte Paschi May Lower Threshold for Mediobanca Bid: Repubblica
Monte Paschi could reduce the threshold to 51% or lower from the current rate of almost 67%, the newspaper said. Chief Executive Officer Luigi Lovaglio is willing to ease the condition to reflect a widening divergence in the share prices of both banks after Mediobanca's recent rally, according to the report.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
O'Riley's price tag, Roma eye Sancho and Gosens: today's transfer news 🤑
The start of the championship is getting closer and all Serie A teams are pushing in the market to try to strengthen as much as possible. Not in Italy but still want to watch Atalanta-Juventus? Do it on OneFootball! Purchase the match (viewable only outside Italy) for 2.99 euros. Below, as usual, are the most important news for the top teams in our championship. Juventus, the price of O'Riley Despite the full availability shown by the midfielder towards Juventus, Brighton does not seem willing to offer discounts for Matt O'Riley. According to the Quotidiano Sportivo, the English club has set the price at no less than 30 million euros to let the Anglo-Danish player born in 2000 leave. A figure that the Bianconeri could only guarantee through a significant sale. Not in Italy but still want to watch Atalanta-Juventus? Do it on OneFootball! Purchase the match (viewable only outside Italy) for 2.99 euros. For this reason, the negotiation with Nottingham Forest for Douglas Luiz becomes even more relevant. The potential sale of the Brazilian would indeed allow Juventus to have the necessary resources to strike a deal for O'Riley. The club's strategy remains tied to a series of market maneuvers. Milan, Lazetic leaving. The formula Marko Lazetic is close to leaving Milan. As reported by Gianluca Di Marzio on X, the Serbian forward is expected in Scotland today to finalize the transfer to Aberdeen, where he will undergo medical examinations tomorrow. The 2004-born player will leave the Rossoneri on a free transfer, but the club on Via Aldo Rossi will retain a percentage on the player's future resale. Inter, stalemate in the sale of Palacios Inter continues to work on outgoing transfers, but the negotiation for Tomas Palacios' move to Basel has experienced a significant slowdown. The deal, which seemed close to conclusion, has stalled in recent hours. According to the dispute concerns the buyout price: the Nerazzurri are asking for 5-6 million euros, while the Swiss club aims to spend much less. The situation is at a standstill and other clubs are starting to consider stepping in for the former Monza defender. Napoli, Juanlu details Antonio Conte is close to welcoming a new reinforcement for his Napoli. It is Juanlu Sanchez, who is increasingly close to wearing the blue jersey. The negotiation, which has been ongoing for some time, seems to be entering the decisive phase with the Neapolitan club ready to speed things up. According to Gianluca Di Marzio, Monday could prove to be a decisive day for the final closure of the operation. Sevilla, which has now decided to sell the player, should receive about 17 million euros from the deal. Roma, waiting for Sancho's response Roma is waiting for Jadon Sancho: the English player has the Giallorossi's proposal on the table and the capital club is waiting to close the deal. As reported by Fabrizio Romano, Manchester United is ready to accept the offer that reaches 23 million euros between loan and purchase obligation. The Red Devils are pushing for the sale to free up the salary and raise funds. The Englishman must decide, and the agents are in contact with Roma. Lazio, Gila talks about Real Madrid Mario Gila, speaking to Radio Marca, commented on the rumors about Real Madrid: 'Being linked is pleasing, Raul at Castilla helped me grow as a man and player'. On his current situation with the Biancocelesti: 'We have quality and Pedro's experience. Without cups, we can prepare better, the goal is Europe and the Champions League would be a dream'. Finally, the derby and future: 'It's the most important match in Italy, winning would give confidence. Sarri has clear ideas, following him will bring great results. The national team call-up remains a unique emotion'. Fiorentina, the latest on Gosens According to Atalanta has made an offer of 12 million euros to bring Robin Gosens back to Bergamo, currently at Fiorentina. However, the Viola club has rejected the proposal, despite the Nerazzurri also relying on the player's connection with the city and some former teammates like De Roon. Fiorentina does not intend to open to the sale, not even in case of a higher bid from Atalanta. Only particularly high offers, perhaps from foreign clubs, could make the management reconsider, provided Gosens is willing to accept. At the moment, Pioli considers the winger an indispensable starter. This article was translated into English by Artificial Intelligence. You can read the original version in 🇮🇹 here. 📸 Gabriele Maltinti - 2025 Getty Images
Yahoo
4 hours ago
- Yahoo
Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) is definitely on the radar of institutional investors who own 38% of the company
Explore Drugs Made In America Acquisition's Fair Values from the Community and select yours Key Insights Significantly high institutional ownership implies Drugs Made In America Acquisition's stock price is sensitive to their trading actions 51% of the business is held by the top 9 shareholders Ownership research, combined with past performance data can help provide a good understanding of opportunities in a stock We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Every investor in Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) should be aware of the most powerful shareholder groups. The group holding the most number of shares in the company, around 38% to be precise, is institutions. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Since institutional have access to huge amounts of capital, their market moves tend to receive a lot of scrutiny by retail or individual investors. Therefore, a good portion of institutional money invested in the company is usually a huge vote of confidence on its future. Let's delve deeper into each type of owner of Drugs Made In America Acquisition, beginning with the chart below. Check out our latest analysis for Drugs Made In America Acquisition What Does The Institutional Ownership Tell Us About Drugs Made In America Acquisition? Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. As you can see, institutional investors have a fair amount of stake in Drugs Made In America Acquisition. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Drugs Made In America Acquisition's historic earnings and revenue below, but keep in mind there's always more to the story. It would appear that 16% of Drugs Made In America Acquisition shares are controlled by hedge funds. That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher. The company's largest shareholder is Drugs Made In America Acquisition LLC, with ownership of 12%. Karpus Management Inc. is the second largest shareholder owning 6.9% of common stock, and First Trust Capital Management L.P. holds about 6.2% of the company stock. We also observed that the top 9 shareholders account for more than half of the share register, with a few smaller shareholders to balance the interests of the larger ones to a certain extent. While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. We're not picking up on any analyst coverage of the stock at the moment, so the company is unlikely to be widely held. Insider Ownership Of Drugs Made In America Acquisition The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it. Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances. We can see that insiders own shares in Drugs Made In America Acquisition Corp.. As individuals, the insiders collectively own US$4.1m worth of the US$345m company. It is good to see some investment by insiders, but it might be worth checking if those insiders have been buying. General Public Ownership The general public-- including retail investors -- own 32% stake in the company, and hence can't easily be ignored. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run. Private Company Ownership We can see that Private Companies own 12%, of the shares on issue. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company. Next Steps: I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Be aware that Drugs Made In America Acquisition is showing 4 warning signs in our investment analysis , and 2 of those make us uncomfortable... If you would prefer check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, backed by strong financial data. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
5 hours ago
- Bloomberg
Mediobanca Investors Tender 13% in Paschi Bid's First Big Win
Mediobanca SpA investors tendered about 13% of the company's shares to Banca Monte dei Paschi di Siena SpA, giving the Siena-based lender the first significant win in a takeover bid for its Milanese rival. The Mediobanca shares were tendered on Thursday, according to an Italian stock exchange filing made that evening, before a national holiday Friday. The filing didn't disclose whose shares they were. The previous day's filing showed only 0.06% had been tendered.
